154 related articles for article (PubMed ID: 32559820)
1. Model informed dosing of hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and gaps.
Thémans P; Dauby N; Schrooyen L; Lebout F; Delforge M; Nasreddine R; Libois A; Payen MC; Konopnicki D; Wuillaume F; Lescrainier C; Verlinden V; Dogné JM; Hamdani J; Musuamba FT
Br J Clin Pharmacol; 2021 Feb; 87(2):674-682. PubMed ID: 32559820
[TBL] [Abstract][Full Text] [Related]
2. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
[TBL] [Abstract][Full Text] [Related]
3. Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations.
Karatza E; Ismailos G; Marangos M; Karalis V
Xenobiotica; 2021 Feb; 51(2):127-138. PubMed ID: 32933365
[TBL] [Abstract][Full Text] [Related]
4. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Maharaj AR; Wu H; Hornik CP; Balevic SJ; Hornik CD; Smith PB; Gonzalez D; Zimmerman KO; Benjamin DK; Cohen-Wolkowiez M;
JAMA Pediatr; 2020 Oct; 174(10):e202422. PubMed ID: 32501511
[TBL] [Abstract][Full Text] [Related]
5. Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.
Garcia-Cremades M; Solans BP; Hughes E; Ernest JP; Wallender E; Aweeka F; Luetkemeyer AF; Savic RM
Clin Pharmacol Ther; 2020 Aug; 108(2):253-263. PubMed ID: 32285930
[TBL] [Abstract][Full Text] [Related]
6. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
[TBL] [Abstract][Full Text] [Related]
7. Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016.
Melles RB; Jorge AM; Marmor MF; Zhang Y; Choi HK
Clin Rheumatol; 2018 Jul; 37(7):1853-1859. PubMed ID: 29696437
[TBL] [Abstract][Full Text] [Related]
8. Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized Hydroxychloroquine for Pulmonary Delivery to COVID-19 Patients.
Idkaidek N; Hawari F; Dodin Y; Obeidat N
Drug Res (Stuttg); 2021 May; 71(5):250-256. PubMed ID: 33378773
[TBL] [Abstract][Full Text] [Related]
9. Interpreting hydroxychloroquine blood levels for medication non-adherence: a pharmacokinetic study.
Balevic S; Sun K; Rogers JL; Eudy A; Sadun RE; Maheswaranathan M; Doss J; Criscione-Schreiber L; O'Malley T; Clowse M; Weiner D
Lupus Sci Med; 2024 Apr; 11(1):. PubMed ID: 38688714
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.
Thémans P; Belkhir L; Dauby N; Yombi JC; De Greef J; Delongie KA; Vandeputte M; Nasreddine R; Wittebole X; Wuillaume F; Lescrainier C; Verlinden V; Kiridis S; Dogné JM; Hamdani J; Wallemacq P; Musuamba FT
Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):703-713. PubMed ID: 32968954
[TBL] [Abstract][Full Text] [Related]
12. Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines.
Jorge AM; Melles RB; Zhang Y; Lu N; Rai SK; Young LH; Costenbader KH; Ramsey-Goldman R; Lim SS; Esdaile JM; Clarke AE; Urowitz MB; Askanase A; Aranow C; Petri M; Choi H
Arthritis Res Ther; 2018 Jul; 20(1):133. PubMed ID: 29976231
[TBL] [Abstract][Full Text] [Related]
13. Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients.
Perinel S; Launay M; Botelho-Nevers É; Diconne É; Louf-Durier A; Lachand R; Murgier M; Page D; Vermesch R; Thierry G; Delavenne X
Clin Infect Dis; 2020 Nov; 71(16):2227-2229. PubMed ID: 32255489
[TBL] [Abstract][Full Text] [Related]
14. Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19.
Ruiz S; Concordet D; Lanot T; Georges B; Goudy P; Baklouti S; Mané C; Losha E; Vinour H; Rousset D; Lavit M; Minville V; Conil JM; Gandia P
Int J Antimicrob Agents; 2021 Feb; 57(2):106247. PubMed ID: 33259916
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis.
Carmichael SJ; Charles B; Tett SE
Ther Drug Monit; 2003 Dec; 25(6):671-81. PubMed ID: 14639053
[TBL] [Abstract][Full Text] [Related]
16. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
[TBL] [Abstract][Full Text] [Related]
17. Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19.
Cui C; Tu S; En VSJ; Li X; Yao X; Li H; Liu D
Curr Drug Metab; 2020; 21(6):427-435. PubMed ID: 32520683
[TBL] [Abstract][Full Text] [Related]
18. A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS-CoV-2(-)/(+) populations.
Steinbronn C; Chhonker YS; Stewart J; Leingang H; Heller KB; Krows ML; Paasche-Orlow M; Bershteyn A; Stankiewicz Karita HC; Agrawal V; Laufer M; Landovitz R; Wener M; Murry DJ; Johnston C; Barnabas RV; Arnold SLM
Clin Transl Sci; 2023 Jul; 16(7):1243-1257. PubMed ID: 37118968
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
Morita S; Takahashi T; Yoshida Y; Yokota N
Ther Drug Monit; 2016 Apr; 38(2):259-67. PubMed ID: 26587870
[TBL] [Abstract][Full Text] [Related]
20. Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption.
Takamasu E; Yokogawa N; Shimada K; Sugii S
Lupus; 2019 Oct; 28(12):1473-1476. PubMed ID: 31575325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
